Want to see TARS full AI Analyst Report?
TARS Stock Chart & Stats
$67.24
$0.07(0.13%)
At close: 4:00 PM EST
$67.24
$0.07(0.13%)
Day’s Range― - ―
52-Week Range$38.51 - $85.25
Previous CloseN/A
Volume127.14K
Average Volume (3M)851.12K
Market Cap
$2.91B
Enterprise Value$2.68B
Total Cash (Recent Filing)$388.73M
Total Debt (Recent Filing)$88.68M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Aug 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding43,023,960
10 Day Avg. Volume1,338,911
30 Day Avg. Volume851,124
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)9.96
Price to Sales (P/S)7.58
P/FCF Ratio-153.35
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue5.00
Enterprise Value/Gross Profit5.53
Enterprise Value/Ebitda-66.64
Forecast
1Y Price Target
$94.29Price Target Upside40.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$696.32M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue GrowthConsistently strong revenue growth combined with exceptionally high gross margins (~90%+) indicates durable product-level economics and pricing power. These fundamentals support scalable unit economics, margin sustainability, and the ability to reinvest in commercialization and pipeline over the next several quarters.
Reiterated Guidance And Commercial MomentumManagement's reiterated full-year guidance and Q1 XTENVI sales growth (>85% YoY) reflect persistent demand, expanding prescriber adoption, and improving DTC engagement. Durable commercial traction and planned key-account hires should deepen penetration and sustain revenue growth over the medium term.
Conservative Leverage And Balance Sheet FlexibilityA relatively modest debt load versus a sizable equity base provides financial flexibility to fund ongoing commercialization and selective R&D without immediate refinancing strain. This conservative leverage profile supports strategic optionality for partnerships or late‑stage development needs.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow means the business still consumes external capital despite revenue gains. Until cash generation turns positive, the company will likely depend on financing, partner payments, or milestones to fund growth and potential Phase III programs, adding execution risk.
Ongoing Operating LossesDespite improving top-line trends, negative net margins and returns show the company has not reached sustained profitability. Continued elevated SG&A and R&D investments implied by guidance could extend the loss profile, pressuring returns and necessitating disciplined capital allocation to reach breakeven.
Development & Recurring Revenue UncertaintyRetreatment rates remain in the mid-to-high teens below the ~20% steady state, limiting predictability of recurring revenues. Separately, management expects to partner for a potentially large Phase III, creating execution and dependency risk that could delay or dilute value capture from mid-stage pipeline programs.
Tarsus Pharmaceuticals News
TARS FAQ
What was Tarsus Pharmaceuticals, Inc.’s price range in the past 12 months?
Tarsus Pharmaceuticals, Inc. lowest stock price was $38.51 and its highest was $85.25 in the past 12 months.
What is Tarsus Pharmaceuticals, Inc.’s market cap?
Tarsus Pharmaceuticals, Inc.’s market cap is $2.91B.
When is Tarsus Pharmaceuticals, Inc.’s upcoming earnings report date?
Tarsus Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 28 days.
How were Tarsus Pharmaceuticals, Inc.’s earnings last quarter?
Tarsus Pharmaceuticals, Inc. released its earnings results on May 06, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.4 by $0.24.
Is Tarsus Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Tarsus Pharmaceuticals, Inc. pay dividends?
Tarsus Pharmaceuticals, Inc. does not currently pay dividends.
What is Tarsus Pharmaceuticals, Inc.’s EPS estimate?
Tarsus Pharmaceuticals, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Tarsus Pharmaceuticals, Inc. have?
Tarsus Pharmaceuticals, Inc. has 43,023,960 shares outstanding.
What happened to Tarsus Pharmaceuticals, Inc.’s price movement after its last earnings report?
Tarsus Pharmaceuticals, Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.4. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in TARS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tarsus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$94.29 (40.22% Upside)
$94.29 (40.22% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 245.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
76.68%
12-Months-Change
Fundamentals
Return on Equity
-14.19%
Trailing 12-Months
Asset Growth
16.05%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
TARS Company Deck
TARS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted robust commercial momentum for XTENVI with a strong Q1 showing (>$145M, >85% YoY growth), growing prescriber adoption, improving DTC engagement (+~40% QoQ high-value activity), pipeline progress with two Phase II programs initiated and reiterated full-year guidance. Headwinds were largely expected and manageable: seasonal/deductible effects and weather impact in Q1, retreatment rates still progressing toward steady-state (~20%), limited near-term international royalties, and the one-time nature of a China milestone. Management emphasized continued execution, targeted commercial investments (Key Account Leaders), and confidence in achieving guidance and future growth drivers.View all TARS earnings summariesTARS Stock 12 Month Forecast
Average Price Target
$94.29
▲(40.22% Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
3.26% Insiders
21.54% Mutual Funds
2.23% Other Institutional Investors
60.49% Public Companies and
Individual Investors